Randomized trial · people
ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg arm
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this short human trial, ARA-290 increased small nerve fibers in the eye and skin at the 4 mg dose. The evidence that it eases pain more than placebo is less clear.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 64
- Published
- 2017
- Journal
- Invest Ophthalmol Vis Sci
What they tested
Does daily cibinetide (ARA-290) regrow small nerve fibers and ease nerve pain in people with sarcoidosis who have lost small nerve fibers?
How the study was done
A phase 2b, randomized, placebo-controlled trial in 64 people with sarcoidosis-linked small nerve fiber loss and nerve pain. They got 1, 4 or 8 mg of cibinetide a day or placebo (a dummy treatment) for 28 days. The main measure was the change in corneal nerve fiber area, which counts nerve fibers in the eye's clear front layer using a special microscope.

What they found
Compared with placebo, corneal nerve fiber area rose by 697 μm2 in the 4 mg arm (P = 0.012). The 109 μm2 rise in the 1 mg arm and the 431 μm2 rise in the 8 mg arm were not statistically clear. The 4 mg arm also gained regrowing nerve fibers in the skin (GAP-43+ fibers, P = 0.035), and changes in corneal nerve area tracked with changes in skin nerve fibers (ρ = 0.575) and in the 6-minute walk test (ρ = 0.645). Pain improved significantly in all groups. Among people with moderate to severe pain, the 4 mg arm had a placebo-corrected drop described as clinically meaningful (P = 0.157).
What it doesn’t show
It was a small, 28-day trial split across four arms, and only the 4 mg dose clearly beat placebo on the main measure. Nerve fiber counts are stand-in measures for the disease, and the pain result for people with moderate to severe pain came from a subgroup, with P = 0.157.
The paper
Culver et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Invest Ophthalmol Vis Sci. 2017.
The compound
More studies on ARA-290
- ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber lossRandomized trial · people · 2013
- ARA-290 improved small fiber neuropathy symptoms in sarcoidosisRandomized trial · people · 2012
- ARA-290 eased nerve-injury pain for up to 20 weeks in ratsAnimal study · rats · 2014
- Every study on ARA-290
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.